1461084241-b824531a-3165-42a6-ac4a-45b0424e5e99

1. A slaked lime composition comprising Ca(OH)2 particles with a platy crystalline morphology, or platelets, the platelets having a diameter D between 1 \u03bcm and 80 \u03bcm of the circle circumscribing the platelet and a thickness e between 0.05 \u03bcm and 1 \u03bcm, as well as an aspect ratio consisting of the ratio between the diameter D of the circle circumscribing the platelet and the thickness e,
characterized in that the composition has a platelet content between 50 and 100% based on the total of the Ca(OH)2 particles, and in that the aspect ratio is between 10 and 300.
2. The slaked lime composition according to claim 1, wherein the aspect ratio De is between 20 and 200.
3. The slaked lime composition according to claim 1, wherein the aspect ratio De is between 30 and 100.
4. The slaked lime composition according to claim 1, wherein the aspect ratio De is between 45 and 80.
5. The slaked lime composition according to claim 1, wherein the particles having a platy crystalline morphology have a hexagonal platy crystalline morphology.
6. The slaked lime composition according to claim 1, wherein the platelet content is greater than 70%, based on the total of the Ca(OH)2 particles.
7. The slaked lime composition according to claim 1, wherein the platelet content is greater than 80%, based on the total of the Ca(OH)2 particles.
8. The slaked lime composition according to claim 1, wherein the platelet content is greater than 90%, based on the total of the Ca(OH)2 particles.
9. The slaked lime composition according to claim 1, wherein the dimension D is between 1 \u03bcm and 80 \u03bcm.
10. The slaked lime composition according to claim 1, wherein the dimension D is between 2 \u03bcm and 40 \u03bcm.
11. The slaked lime composition according to claim 1, wherein the dimension D is between 3 \u03bcm and 30 \u03bcm.
12. The slaked lime composition according to claim 1, wherein the thickness e is between 0.05 \u03bcm and 1 \u03bcm.
13. The slaked lime composition according to claim 1, wherein the thickness e is between 0.1 \u03bcm and 0.5 \u03bcm.
14. The slaked lime composition according to claim 1, having a sulfur content between 0.01% and 1.5%, based on the weight of the composition.
15. The slaked lime composition according to claim 1, having a diethylene glycol content between 0.1% and 2%, based on the weight of the composition.
16. The composition according to claim 1, wherein calcium hydroxide is present in an amount ranging from 80% to 98% by weight, based on the total weight of the composition.
17. The composition according to claim 1, wherein calcium hydroxide is present in an amount ranging from 85% to 97% by weight, based on the total weight of the composition.
18. The composition according to claim 1, wherein calcium hydroxide is present in an amount ranging from 90% to 96% by weight, based on the total weight of the composition.
19. The composition according to claim 1, wherein calcium hydroxide is present in an amount ranging from 92% to 95% by weight, based on the total weight of the composition.
20. A slaked lime composition comprising Ca(OH)2 particles with a platy crystalline morphology, or platelets, the platelets having a diameter D between 1 \u03bcm and 80 \u03bcm of the circle circumscribing the platelet and a thickness e between 0.05 \u03bcm and 1 \u03bcm, the slaked lime being made by mixing quicklime, slaking water, a sulfur containing mineral additive and diethylene glycol.
21. A method for manufacturing slaked lime from quicklime comprising:
a mixture of quicklime, slaking water, a sulfur-containing mineral additive and diethylene glycol,
slaking of the quicklime by the slaking water in the presence of the sulfur-containing mineral additive and diethylene glycol,
formation of Ca(OH)2 platelets having a diameter D between 1 \u03bcm and 80 \u03bcm of the circle circumscribing the platelet and a thickness e between 0.05 \u03bcm and 1 \u03bcm, as well as an aspect ratio consisting of a ratio of the diameter of the circle circumscribing the platelet to the thickness between 10 and 300, at a platelet content between 50 and 100% based on the total of the formed Ca(OH)2 particles.
22. The method according to claim 21, wherein the sulfur-containing mineral additive is added to the quicklime and diethylene glycol is added to the slaking water.
23. The method according to claim 21, wherein the sulfur-containing mineral additive and diethylene glycol are added to the slaking water.
24. The method according claim 21, further comprising maturation of the mixture for 12 to 24 hours.
25. The method according to claim 21, wherein the sulfur-containing mineral additive is selected from the group consisting of sulfates, sulfites, bisulfates and bisulfites having a solubility at 20\xb0 C. greater than or equal to 1 gdm3.
26. The method according to claim 21, wherein the sulfur-containing mineral additive is selected from the group consisting of CaSO4, MgSO4, Na2SO3, NaHSO4, NaHSO3, and mixtures thereof.
27. The method according to claim 21, wherein the sulfur-containing mineral additive is added in an amount between 0.1% and 5%, by weight of anhydrous additive based on the weight of the quicklime.
28. The method according to claim 21, wherein the sulfur-containing mineral additive is added in an amount between 0.3% and 2.5% by weight of anhydrous additive based on the weight of the quicklime.
29. The method of claim 21, wherein the sulfur-containing mineral additive is added in an amount between 0.5% and 1.5% by weight of anhydrous additive based on the weight of the quicklime.
30. The method according to claim 21, wherein diethylene glycol is added in an amount ranging from 0.1% to 2.5% by weight based on the weight of quicklime.
31. The method according to claim 21, wherein diethylene glycol is added in an amount ranging from 0.2% to 1% by weight based on the weight of quicklime.
32. The method according to claim 21, wherein diethylene glycol is added in an amount ranging from 0.3% to 0.6% by weight based on the weight of quicklime.
33. The method according to claim 21, wherein the water is added for the slaking in a quicklimewater weight ratio between 11.5 and 112.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A system for assessing athletic performance, comprising:
a protective housing for attachment to a person or to a human-powered sport vehicle;
a GPS sensor configured with the housing for generating earth position signals;
a microprocessor configured with the housing for processing the signals to determine at least one of speed and distance traveled of the person or human-powered sport vehicle; and
a data unit for reporting one or both of the speed and distance traveled to the person or to a user of the human-powered sport vehicle.
2. The system of claim 1, further comprising memory for storing map data from which the microprocessor reports features along a path taken by the person or sport vehicle.
3. The system of claim 1, further comprising memory for storing map data, the processor configured to display, on the data unit, a user position using the map data.
4. The system of claim 1, the sport vehicle comprising a bike.
5. The system of claim 1, the sport vehicle comprising a snowboard, ski, windsurf board or mask, roller blade boot, skate board, or kayak.
6. The system of claim 1, further comprising a wireless transmitter configured with the housing for transmitting data indicative of one or both of the speed and distance traveled to the data unit.
7. The system of claim 6, further comprising a wireless receiver configured with the data unit for receiving the data from the wireless transmitter.
8. The system of claim 7, wherein the data unit comprises a display.
9. The system of claim 8, the data unit comprising a watch.
10. The system of claim 7, further comprising headphones for audibly reporting one or both of the speed and distance traveled to the person or user.
11. The system of claim 7, wherein the GPS sensor is integrated with clothing to be worn by the person.
12. The system of claim 1, further comprising memory for storing map data, wherein the microprocessor utilizes the map data in determining one or both of the speed and distance traveled.
13. A system of claim 1, further comprising memory for storing at least one map, the microprocessor configured to identify terrain features near to the person and based on the map.
14. A system for assessing sporting performance, comprising:
a protective housing for attachment to a person or to a human-powered sport vehicle;
a GPS sensor configured with the housing for generating earth position signals;
a microprocessor configured with the housing for processing the signals to determine sporting performance data associated with the person or the human-powered sport vehicle;
a data unit for reporting the sporting performance data to the person or to a user of tho human-powered sport vehicle;
a wireless transmitter for wirelessly transmitting the sporting performance data; and
a wireless receiver connected with the data unit for wirelessly receiving the sporting performance data.
15. The system of claim 14, the microprocessor further configured to determine, from signals of the GPS sensor, one or more of drop distance, airtime, distance traveled, speed and height, as the sporting performance data.
16. The system of claim 14, further comprising memory for storing map data, wherein the microprocessor utilizes the map data in determining the sporting performance data.
17. A system of claim 14, further comprising memory for storing at least one map, the microprocessor configured to identify terrain features near to the person and based on the map.

1461084231-7df6d32f-a285-4548-ab3e-f567f490ac75

1. An apparatus comprising:
an antenna for generating an electromagnetic field for an electromagnetic transponder, the antenna comprising:
a first inductive element operative to connect to two terminals of application of an excitation voltage; and
a parallel resonant circuit coupled with the first inductive element to extend a range of an electromagnetic field emitted by the first inductive element, and
wherein the parallel resonant circuit comprises a second inductive element and a control switch connected to the second inductive element.
2. The antenna of claim 1, wherein the control switch is connected in parallel with the second inductive element.
3. The antenna of claim 1, wherein the control switch is connected in series with the second inductive element.
4. An apparatus comprising:
an antenna for generating an electromagnetic field for an electromagnetic transponder, the antenna comprising:
a first inductive element operative to connect to two terminals of application of an excitation voltage; and
a parallel resonant circuit coupled with the first inductive element to extend a range of an electromagnetic field emitted by the first inductive element,
wherein the parallel resonant circuit comprises a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element is formed of several inductances organized in a network, and
wherein the several inductances comprise seven planar windings.
5. The antenna of claim 4, wherein the seven windings are distributed in a honeycomb formation, such that each side of one planar winding of the seven planar windings is adjacent to a single side of each of the other six planar windings of the seven planar windings.
6. An apparatus comprising:
an antenna for generating an electromagnetic field for an electromagnetic transponder, the antenna comprising:
a first inductive element operative to connect to two terminals of application of an excitation voltage; and
a parallel resonant circuit coupled with the first inductive element to extend a range of an electromagnetic field emitted by the first inductive element,
wherein the parallel resonant circuit comprises a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element and the second inductive element are formed of planar windings, and
wherein a value of the second inductive element is greater than a value of the first inductive element.
7. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and
a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element and the second inductive element each comprise a planar winding,
wherein a plane of the first inductive element and a plane of the second inductive element are substantially parallel, and
wherein the first inductive element comprises a plurality of planar windings.
8. The antenna of claim 7, wherein the planar winding of the second inductive element has a substantially same planar shape and size as a planar shape and size of a perimeter of the plurality of planar windings.
9. The antenna of claim 7, wherein at least one planar winding of the plurality of planar windings has a substantially hexagonal geometry.
10. The antenna of claim 7, wherein the plurality of planar windings includes seven planar windings, each winding of the seven planar windings having a substantially hexagonal geometry.
11. The antenna of claim 10, wherein the seven planar windings are distributed in a honeycomb formation, such that each side of one planar winding of the seven planar windings is adjacent to a single side of each of the other six planar windings of the seven planar windings.
12. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and
a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element and the second inductive element each comprise a planar winding,
wherein a plane of the first inductive element and a plane of the second inductive element are substantially parallel,
wherein the resonant circuit further comprises a first capacitor, and wherein the first capacitor is connected in parallel to the second inductive element, and
wherein a value of the first capacitor and a value of the second inductive element define a natural frequency approximately equal to a frequency of the excitation signal.
13. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and
a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element,
wherein the first inductive element and the second inductive element each comprise a planar winding,
wherein a plane of the first inductive element and a plane of the second inductive element are substantially parallel,
wherein the resonant circuit further comprises a first capacitor, and wherein the first capacitor is connected in parallel to the second inductive element, and
wherein the resonant circuit further comprises a switch.
14. The antenna of claim 13, wherein the switch is in parallel with the second inductive element.
15. The antenna of claim 13, wherein the switch is in series with the second inductive element.
16. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and
a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element and the resonant circuit are disposed on a same substrate.
17. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element and a control switch connected to the second inductive element,
wherein the first inductive element and the resonant circuit are disposed on a same substrate wherein the first inductive element comprises a plurality of planar windings.
18. The antenna of claim 17, wherein the second inductive element comprises a planar winding, and wherein the planar winding of the second inductive element has a substantially same planar shape and size as a planar shape and size of a perimeter of the plurality of planar windings.
19. The antenna of claim 17, wherein at least one planar winding of the plurality of planar windings has a substantially hexagonal geometry.
20. The antenna of claim 17, wherein the plurality of planar windings includes seven planar windings, each winding of the seven planar windings having a substantially hexagonal geometry.
21. The antenna of claim 20, wherein the seven planar windings are distributed in a honeycomb formation, such that each side of one planar winding of the seven planar windings is adjacent to a single side of each of the other six planar windings of the seven planar windings.
22. An apparatus comprising:
an antenna comprising:
a first inductive element configured to connect to an excitation signal; and
a resonant circuit to extend a range of an electromagnetic field emitted by the first inductive element, the resonant circuit being configured to inductively couple to the first inductive element, the resonant circuit comprising a second inductive element and a switch connected to the second inductive element,
wherein the first inductive element and the resonant circuit are disposed on a same substrate,
wherein the resonant circuit further comprises a first capacitor, and wherein the first capacitor is connected in parallel to the second inductive element, and
wherein a value of the first capacitor and a value of the second inductive element define a natural frequency approximately equal to a frequency of the excitation signal.
23. The antenna of claim 22, wherein the switch is in parallel with the second inductive element.
24. The antenna of claim 22, wherein the switch is in series with the second inductive element.
25. A terminal for generating a high-frequency electromagnetic field for at least one transponder entering this field, the terminal comprising:
an antenna for generating an electromagnetic field for the at least one transponder, the antenna comprising:
a resonant circuit and an excitation circuit magnetically coupled to the resonant circuit, the excitation circuit including a first inductive element and having no capacitive element, said resonant circuit including a second inductive element and a control switch connected to the second inductive element, a value of which is chosen to be greater than a value of the first inductive element with a ratio depending on a desired field amplification for extending a range of an electromagnetic field emitted by the excitation circuit.
26. The terminal of claim 25, further comprising a current transformer connected to the resonant circuit.
27. The terminal of claim 25, further comprising a current transformer connected to the excitation circuit.
28. The terminal of claim 25, wherein the first inductive element comprises seven planar windings.
29. The terminal of claim 28, wherein the seven windings are distributed in a honeycomb formation, such that each side of one planar winding of the seven planar windings is adjacent to a single side of each of the other six planar windings of the seven planar windings.
30. The terminal of claim 25, wherein the control switch is connected in series with the second inductive element.
31. The terminal of claim 25, wherein the control switch is connected in parallel with the second inductive element.
32. The terminal of claim 25, wherein the resonant circuit is formed of the second inductive element and of a capacitive element in parallel, and is tuned to the frequency of an excitation signal of the first inductive element.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound represented by the following formula I or a pharmaceutically acceptable salt thereof, or a solvate thereof:
wherein
ring A is a monocyclic heterocyclic group optionally substituted by 1 to 5 substituents selected from the following group A, wherein the monocyclic heterocyclic group contains, besides carbon atom, at least one hetero atom selected from nitrogen atom, oxygen atom and sulfur atom;
group A is a group consisting of halogen atom, C1-4 alkyl group, \u2014(CH2)n\u2014ORa1, \u2014NRa3Ra4, \u2014CORa2 and \u2014CONRa3Ra4, wherein Ra1, Ra2, Ra3 and Ra4 are the same or different and each is a hydrogen atom or a C1-4 alkyl group, and n is 0 or an integer of 1 to 4;
R1 is a hydrogen atom,
a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from the following group B,
a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or
a heterocyclic group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, wherein the heterocyclic group contains, besides carbon atom, at least one hetero atom selected from nitrogen atom, oxygen atom and sulfur atom;
group B is a group consisting of
a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A,
a heterocyclic group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, wherein the heterocyclic group is as defined above,
halogen atom, cyano group,
\u2014ORb1, \u2014SRb1, \u2014NRb2Rb3,
\u2014CONRb2Rb3, \u2014SO2NRb2Rb3, \u2014CORb1,
\u2014NRb2CORb1, \u2014SO2Rb1, \u2014NRb2SO2Rb1,
\u2014COORb1, \u2014NRb2COORb1 and \u2014NRb4CO\u2014NRb2Rb3
wherein Rb1, Rb2, Rb3 and Rb4 are the same or different and each is a hydrogen atom, a C1-4 alkyl group, a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or a heterocyclic group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, wherein the heterocyclic group is as defined above;
R2 is a hydrogen atom, a C1-4 alkyl group or \u2014OR11, wherein R11 is a hydrogen atom or a C1-4 alkyl group;
R3 and R4 are the same or different and each is a hydrogen atom, a halogen atom, a C1-4 alkyl group or \u2014OR R12, wherein R12 is a hydrogen atom or a C1-4 alkyl group;
R5 is each independently, a halogen atom, a C1-4 alkyl group or \u2014OR R13, wherein R13 is a hydrogen atom or a C1-4 alkyl group;
m is 0, 1 or 2; and
R6 is a hydrogen atom, or R1 and R6 form, together with the carbon atoms bonded thereto, a C3-10 cycloalkyl group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A.
2. The compound of claim 1, wherein ring A is a monocyclic heterocyclic group containing at least one nitrogen atom, said monocyclic heterocyclic group is optionally substituted by 1 to 5 substituents selected from group A and bonded, via the nitrogen atom, to the benzene ring, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
3. The compound of claim 2, wherein ring A is a heterocyclic group selected from 1-pyrrolidinyl group, 2-oxopyrrolidin-1-yl group, piperidino group, 2-oxopiperidin-1-yl group, 1-piperazinyl group, morpholino group, thiomorpholino group, 3-oxomorpholin -4-yl group, 1,1-dioxoisothiazolidin-2-yl group, 2-oxooxazolidin-3-yl group and 3-oxopyrazolidin-1-yl group, wherein the heterocyclic group is optionally substituted by 1 to 5 substituents selected from group A, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
4. The compound of claim 1, wherein R1 is a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from group B, and R6 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
5. The compound of claim 1, wherein R2 is a C1-4 alkyl group or \u2014OR11, wherein R11 is a hydrogen atom or a C1-4 alkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
6. The compound of claim 1, wherein R2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
7. The compound of claim 1, wherein R3 and R4 are the same or different and each is a halogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
8. The compound of claim 1, wherein m is 1, and R5 is a halogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
9. The compound of claim 1, wherein m is 0, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
10. The compound of claim 1, which is selected from a group consisting of
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((R)-1-ethoxymethyl-2-hydroxyethyl)-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(pyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxooxazolidin-3-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(piperidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopiperidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-((R)-3-hydroxypyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-((S)-3-hydroxypyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-methyl-3-oxopyrazolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-5-(4-acetylpiperazin-1-yl)-3-chloro-2-fluorobenzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-5-(3,3-difluoropyrrolidin-1-yl)-2-fluorobenzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-((R)-3-fluoropyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-((S)-3-fluoropyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((1R,2R)-1-hydroxymethyl-2-methoxypropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((R)-1-ethoxymethyl-2-hydroxyethyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-(R)-2-hydroxy-1-(methoxymethyl)ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-5-(1,1-dioxoisothiazolidin-2-yl)-2-fluorobenzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-(R)-2-hydroxy-1-(methoxymethyl)ethyl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(2-oxopyrrolidin-1-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(thiomorpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((1R,2S)-1-hydroxymethyl-2-methoxypropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-3-methoxypropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(4-hydroxypiperidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((1R,2R)-1-hydroxymethyl-2-methoxypropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((1R,2S)-1-hydroxymethyl-2-methoxypropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(pyridin-2-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(thiazol-2-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-(1R,2R)-2-ethoxy-1-(hydroxymethyl)propyl-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((R)-1-ethoxymethyl-2methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-(1R,2R)-2-ethoxy-1-(hydroxymethyl)propyl-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-14(R)-1-ethoxymethyl-2-hydroxyethyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-(1R,2R)-2-ethoxy-1-(hydroxymethyl)propyl-7-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-7-ethyl-1-((1R,2R)-1-hydroxymethyl -2-methoxypropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((R)-1-hydroxymethyl-2-methoxy-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((R)-1-hydroxymethyl-2-methoxy-2-methylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-3-methoxypropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-3-methoxypropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((1R,2R)-1-hydroxymethyl-2-methoxypropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-(1R,2R)-2-ethoxy-1-(hydroxymethyl)propyl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(2-oxopyrrolidin-1-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(2-oxopyrrolidin-1-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(2-oxopyrrolidin-1-yl)benzyl-7-ethyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(morpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl-1-((S)-1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid,
6-3-chloro-2,4-difluoro-5-(3-oxomorpholin-4-yl)benzyl-1-((S)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, and
6-3-chloro-2,4-difluoro-5-(morpholin-4-yl)benzyl-1-((R)-1-hydroxymethyl-2,2-dimethylpropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
11. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
12. A method for the treatment of an HIV infectious disease in a mammal, which comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
13. The method of claim 12, which further comprises administering an effective amount of one or more other kinds of anti-HIV active substances to the mammal.
14. A method for inhibiting HIV integrase in a mammal, which comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
15. A pharmaceutical composition for inhibiting HIV integrase, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
16. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
17. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
18. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
19. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
20. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
21. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
22. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
23. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
24. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, or a solvate thereof:
25. A pharmaceutical composition comprising the compound of any one of claims 16-24 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
26. A method for the treatment of an HIV infectious disease in a mammal, which comprises administering an effective amount of the compound of any one of claims 16-24 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
27. The method of claim 26, which further comprises administering an effective amount of one or more other kinds of anti-HIV active substances to the mammal.
28. A method for inhibiting HIV integrase in a mammal, which comprises administering an effective amount of the compound of any one of claims 16-24 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.